Biotechnology · Healthcare
CEO, Board Member, Chairman
2023-01-01–present
Board Member
Aclaris Therapeutics, Inc. (ACRS)Chairman
Aclaris Therapeutics, Inc. (ACRS)Equibles does not estimate personal net worth.
Get an email with a short summary when Aclaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACRS alertsNeal Walker is recorded as Board Member at Aclaris Therapeutics, Inc. (ACRS) since June 5, 2025, Chairman at Aclaris Therapeutics, Inc. (ACRS) since January 1, 2023 and CEO at Aclaris Therapeutics, Inc. (ACRS). The newest filing on record that lists Neal Walker as CEO at Aclaris Therapeutics, Inc. (ACRS) is dated April 23, 2026. Aclaris Therapeutics, Inc. reported in an 8-K filed June 5, 2025 that Neal Walker was appointed directors on the Board, effective June 5, 2025. Aclaris Therapeutics, Inc. reported in an 8-K filed January 19, 2024 that Neal Walker was appointed Interim Chief Executive Officer and President, effective January 17, 2024. Aclaris Therapeutics, Inc. reported in an 8-K filed November 22, 2022 that Neal Walker was appointed Chair of the Board, effective January 1, 2023. Equibles holds 4 filed executive changes naming Neal Walker; each is listed under recent activity with its source filing. The proxy statement of Aclaris Therapeutics, Inc. reports total compensation of $3,375,591 for Neal Walker in fiscal 2025, including a base salary of $615,000. Disclosed compensation is on record for 5 fiscal years. Neal Walker has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Aclaris Therapeutics, Inc. on June 4, 2026. Aclaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aclaris Therapeutics, Inc. includes Kevin Balthaser (CFO), Douglas Manion (COO and Board Member), Douglas Manion, M.D., FRCP (C) (COO) and 4 others.
“The stockholders elected three nominees to serve as directors on the Board until the 2028 annual meeting of stockholders and until their respective successors are elected and qualified.”
“In connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company's Interim Chief Executive Officer and President, effective January 17, 2024.”
“And Eclaris is a biotechnology company focused on both large and small molecule therapeutics. We have three assets in the clinic, one on the way into the clinic. and getting into an IND in the back part of this year.”
“Last quarter, we announced that in addition to various cost-cutting measures and an overall review of our business strategy, we were also reevaluating the indication selection for ATI-2138, which is our oral small molecule ITK JAK3 inhibitor.”
2025-06-05–present
2023-01-01–present
Start not stated–present
Last confirmed April 23, 2026
2024-01-17–2022-12-31
Start not stated–2022-12-31
Biotechnology · Healthcare
CEO, Board Member, Chairman
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Aclaris Therapeutics, Inc. (ACRS) | Chief Executive Officer | $615,000 | $3,375,591 |
| 2024 | Aclaris Therapeutics, Inc. (ACRS) | Chief Executive Officer | $477,431 | $1,445,135 |
| 2021 | Aclaris Therapeutics, Inc. (ACRS) | President and Chief Executive Officer | $566,500 | $6,854,936 |
| 2020 | Aclaris Therapeutics, Inc. (ACRS) | President and Chief Executive Officer | $423,784 | $1,610,678 |
| 2019 | Aclaris Therapeutics, Inc. (ACRS) | President and Chief Executive Officer | $499,875 | $3,149,533 |
“Dr. Walker’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Aclaris Therapeutics, Inc. (ACRS)